A forum focusing on intelligent manufacturing and digital technology exchange between China and Japan was held on Oct 12.
Yantai-based biotech innovator RemeGen signed an exclusive worldwide licensing agreement with Seagen Inc on Aug 8.
The actual use of foreign capital in Yantai reached $1.26 billion, up 51.4 percent in the first half of this year.
The signing of the Regional Comprehensive Economic Partnership agreement is a wonderful thing.
Yantai has become a preferred place for multinational firms.
Yantai will host a promotional conference during the second Qingdao Multinationals Summit.